Transcatheter drug delivery through bronchial artery for COVID-19: is it fiction or could it come true?
Eur Radiol Exp
; 4(1): 42, 2020 07 06.
Artículo
en Inglés
| MEDLINE | ID: covidwho-648462
ABSTRACT
More than 1,200 active or recruiting clinical trials for novel coronavirus disease 2019 (COVID-19) treatments and vaccines are registered. Many drugs have shown promise for treatment of COVID-19. Nevertheless, up to date, no drugs have been confirmed as a definitive treatment for COVID-19. Trials such as the SOLIDARITY and RECOVERY are ongoing, and first results were announced in favour of therapy with dexamethasone with a significant trend showing greatest benefit among those patients requiring ventilation. The drawbacks of these trials include exposing the patients to drugs with well-documented systemic adverse effects or unknown complications of novel therapies without proof of clinical benefit. We present here the hypothesis that bronchial artery infusion could be an alternative for systemic drug infusion in COVID-19 trials with superadded benefits of high drug concentration and low systemic adverse effects. The concept of this idea has many uncertainties and no current clinical data to support. Perhaps, the technique should be first applied in animal models to determine its safety and calculate the effective dose of the drugs. Guidelines and reviews of pharmacotherapy for COVID-19 should be implemented for this fiction to come true.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Neumonía Viral
/
Cateterismo Periférico
/
Sistemas de Liberación de Medicamentos
/
Infecciones por Coronavirus
/
Pandemias
/
Betacoronavirus
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Humanos
Idioma:
Inglés
Revista:
Eur Radiol Exp
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
S41747-020-00171-4
Similares
MEDLINE
...
LILACS
LIS